诚信认证:
工商注册信息已核实!
CX-5461
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
阿拉丁 | 生产商 | 上海 | 现货 |
货号 | CAS号 | 操作 |
---|---|---|
C127663-100mg | 1138549-36-6 | 询价 |
C127663-25mg | 1138549-36-6 | 询价 |
C127663-5mg | 1138549-36-6 | 询价 |
- 分子式 C27H27N7O2S
- 分子量513.61
属性
溶解性 |
|
存贮条件 | 储存温度-20°C |
描述
产品介绍 | CX-5461是rRNA合成抑制剂,选择性抑制Pol I驱动的rRNA转录,IC50为142nM,对Pol II无效。 |
备注 | CX-5461 is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA with IC50 of 142 nM, has no effect on Pol II, and possesses 250- to 300-fold selectivity for inhibition of rRNA transcription versus DNA repli |
生化机理 |
CX-5461 is a first-in-class non-genotoxic small molecule targeted inhibitor of RNA polymerase I (Pol I) that activates the p53 pathway without causing DNA damage. CX-5461 selectively inhibits rRNA synthesis by Pol I in the nucleolus, but does not inhibit mRNA synthesis by RNA Polymerase II (Pol II) and does not inhibit DNA replication or protein synthesis. Inhibition of Pol I results in nucleolar stress and release of ribosomal proteins (RP) from the nucleolus. The RP bind to Mdm2 and liberate p53 to orchestrate apoptosis in cancer cells. CX-5461 demonstrates a favorable preclinical profile, potently and selectively kills cancer cells, demonstrates robust in vivo efficacy in multiple models, and has demonstrated oral bioavailability in multiple species. cGMP manufacture has been completed and the molecule is being advanced to the clinic and will be developed for the treatment of leukemias, lymphomas and multiple myeloma. (source: Cylene Pharmaceuticals website) |
别名 | CX 5461;CX5461;2-(4-甲基-1H-1,4-二氮杂环庚烷-1-基)-N-((5-甲基-2-吡嗪基)甲基)-5-氧代-5H-苯并噻唑并(3,2-a)(1,8)萘啶-6-甲酰胺;;CX 5461;CX5461;2-(hexahydro-4-methyl-1h-1,4-diazepin-1-yl)-n-((5-methyl-2-pyrazinyl)methyl)-5-oxo-5h-benzothiazolo(3,2-a)(1,8)naphthyridine-6-carboxamide |
CX-5461信息由上海阿拉丁生化科技股份有限公司为您提供,如您想了解更多关于CX-5461报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途